Skip to Content

Generic Zecuity Availability

Zecuity is a brand name of sumatriptan, approved by the FDA in the following formulation(s):

ZECUITY (sumatriptan succinate - system;iontophoresis)

  • Manufacturer: TEVA BRANDED PHARM
    Approval date: January 17, 2013
    Strength(s): EQ 6.5MG BASE/4HR [RLD]

Has a generic version of Zecuity been approved?

No. There is currently no therapeutically equivalent version of Zecuity available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zecuity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Iontophoretic drug delivery system
    Patent 6,745,071
    Issued: June 1, 2004
    Inventor(s): Carter R.; Anderson & Russell L.; Morris & Clayton J.; Anderson & Lori A.; Grace
    Assignee(s): Birch Point Medical, Inc.
    A reliable, self-contained iontophoretic drug delivery system is disclosed which enjoys a long stable shelf life and which is easy for the user to activate and employ. This system includes a wearable iontophoretic device that is prepackaged as a complete self-contained unit which includes the active species or drug to be administered and counter ions. The system includes a provision for isolating moisture sources from the electrodes and from the power source during storage and provides a simple, user-friendly mechanism to connect the drug to be administered and counter ion reservoirs to the electrodes and the device to the skin of a user in order to activate the device circuit. All elements of the device are contained in a single outer package.
    Patent expiration dates:
    • February 21, 2023
      ✓ 
      Drug product
  • Transdermal methods and systems for the delivery of anti-migraine compounds
    Patent 7,973,058
    Issued: July 5, 2011
    Inventor(s): Anderson; Carter R. & Morris; Russell L. & Sebree; Terri B.
    Assignee(s): NuPathe, Inc.
    Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
    Patent expiration dates:
    • April 12, 2027
      ✓ 
      Patent use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
  • Pharmacokinetics of iontophoretic sumatriptan administration
    Patent 8,155,737
    Issued: April 10, 2012
    Inventor(s): Sebree; Terri B. & Pierce; Mark & O'Neill; Carol
    Assignee(s): NuPathe, Inc.
    Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
    Patent expiration dates:
    • April 12, 2027
      ✓ 
      Patent use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
  • Polyamine enhanced formulations for triptan compound iontophoresis
    Patent 8,366,600
    Issued: February 5, 2013
    Assignee(s): NuPathe Inc.
    A patch and compositions for iontophoresis of triptan compounds are described.
    Patent expiration dates:
    • April 21, 2029
      ✓ 
      Patent use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
  • Transdermal methods and systems for the delivery of anti-migraine compounds
    Patent 8,470,853
    Issued: June 25, 2013
    Assignee(s): NuPathe Inc.
    Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
    Patent expiration dates:
    • April 12, 2027
      ✓ 
      Patent use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
  • Pharmacokinetics of iontophoretic sumatriptan administration
    Patent 8,597,272
    Issued: December 3, 2013
    Assignee(s): Nupathe, Inc.
    Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
    Patent expiration dates:
    • April 12, 2027
      ✓ 
      Drug product
  • Electronic control of drug delivery system
    Patent 8,983,594
    Issued: March 17, 2015
    Assignee(s): NuPathe, Inc.
    In an exemplary embodiment, a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device includes a patch with two electrodes and one or more reservoirs storing a therapeutic agent. The one or more reservoirs release the therapeutic agent into the body surface of the user when the reservoirs are positioned over the electrodes to form an electrical path for the electrotransport current. The device includes a controller which controls a controllable power supply to drive the electrotransport current through the body surface of the user in a predetermined profile.
    Patent expiration dates:
    • November 19, 2030
      ✓ 
      Patent use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
      ✓ 
      Drug product
  • Transdermal methods and systems for the delivery of anti-migraine compounds
    Patent 9,272,137
    Issued: March 1, 2016
    Assignee(s): Teva Pharmaceuticals International GmbH
    Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
    Patent expiration dates:
    • September 7, 2027
      ✓ 
      Drug product
  • User-activated self-contained co-packaged iontophoretic drug delivery system
    Patent 9,327,114
    Issued: May 3, 2016
    Assignee(s): Teva Pharmaceuticals International GmbH
    A user-activated self-contained co-packaged iontophoretic drug delivery system and method of use for treatment of a subject are described.
    Patent expiration dates:
    • October 8, 2032
      ✓ 
      Patent use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
      ✓ 
      Drug product
  • Pharmacokinetics of iontophoretic sumatriptan administration
    Patent 9,427,578
    Issued: August 30, 2016
    Assignee(s): Teva Pharmaceuticals International GmbH
    Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
    Patent expiration dates:
    • April 12, 2027
      ✓ 
      Patent use: METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 17, 2016 - NEW DOSAGE FORM

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide